Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.09.17 | Knight Transportation, Inc. and Swift Transportation Company Merge to Create North America's Premier Truckload Transportation Company | 167 | Business Wire | PHOENIX--(BUSINESS WIRE)--Knight-Swift Transportation Holdings Inc. ("Knight-Swift" or the "Company") (NYSE: "KNX") announced today the completion of the merger of Knight Transportation, Inc. and Swift... ► Artikel lesen | |
10.09.17 | Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial | 150 | Business Wire | Opdivo (nivolumab) plus Yervoy (ipilimumab) reduced the risk of death by 37% versus standard of care, sunitinib, in intermediate- and poor-risk patients The combination also significantly... ► Artikel lesen | |
10.09.17 | Daten aus der ECHO-202-Studie zum progressionsfreien Überleben mit Epacadostat in Kombination mit KEYTRUDA (Pembrolizumab) von Incyte bestätigen die Dauer des Ansprechens bei Patienten mit fortgeschrittenem Melanom | 368 | Business Wire | Aktuelle Daten werden auf dem Kongress der europäischen Gesellschaft für medizinische Onkologie 2017 vorgestellt Die Incyte Corporation (Nasdaq: INCY) gab heute aktuelle Daten aus der... ► Artikel lesen | |
10.09.17 | Top 5 Vendors in the Compensation Software Market From 2017 to 2021: Technavio | 85 | Business Wire | Technavio has announced the top five leading vendors in their recentglobal compensation software marketreport. This research report also lists 22 other prominent vendors that are expected... ► Artikel lesen | |
10.09.17 | Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 | 211 | Business Wire | Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival... ► Artikel lesen | |
10.09.17 | Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 | 213 | Business Wire | - Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival, with... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
AMAZON | 746 |
SUPER MICRO COMPUTER | 726 |
EVOTEC | 533 |
NVIDIA | 450 |
PFIZER | 446 |
TESLA | 410 |
CANOPY GROWTH | 363 |
AMD | 359 |
PAYPAL | 327 |
BYD | 307 |
DEUTSCHE BANK | 298 |
STARBUCKS | 295 |
NEL | 260 |
BARRICK GOLD | 250 |
BAYER | 244 |
TUI | 235 |
AURORA CANNABIS | 198 |
MERCEDES-BENZ | 195 |
PLUG POWER | 189 |
TILRAY BRANDS | 179 |
APPLE | 167 |
CVS HEALTH | 157 |
VOLKSWAGEN | 149 |
COMMERZBANK | 143 |
KRAFT HEINZ | 141 |